IRIS
MONTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.441
AS - Asia 1.375
EU - Europa 1.035
SA - Sud America 194
Continente sconosciuto - Info sul continente non disponibili 93
AF - Africa 70
OC - Oceania 2
Totale 5.210
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.356
CN - Cina 472
SG - Singapore 412
IE - Irlanda 318
HK - Hong Kong 178
RU - Federazione Russa 152
BR - Brasile 148
DE - Germania 141
VN - Vietnam 123
IT - Italia 114
FI - Finlandia 75
FR - Francia 53
GB - Regno Unito 44
CA - Canada 41
ZA - Sudafrica 39
IN - India 35
BD - Bangladesh 26
SE - Svezia 26
ES - Italia 22
AT - Austria 21
MX - Messico 18
AR - Argentina 17
ID - Indonesia 14
IQ - Iraq 13
PK - Pakistan 13
NL - Olanda 12
TR - Turchia 12
JP - Giappone 10
PL - Polonia 10
SA - Arabia Saudita 10
BE - Belgio 9
CO - Colombia 9
EC - Ecuador 8
LT - Lituania 8
MY - Malesia 8
SN - Senegal 8
CZ - Repubblica Ceca 7
EG - Egitto 7
UA - Ucraina 7
JO - Giordania 6
CR - Costa Rica 5
PH - Filippine 5
UZ - Uzbekistan 5
JM - Giamaica 4
NP - Nepal 4
AE - Emirati Arabi Uniti 3
BH - Bahrain 3
DK - Danimarca 3
ET - Etiopia 3
KE - Kenya 3
KZ - Kazakistan 3
LK - Sri Lanka 3
PE - Perù 3
PY - Paraguay 3
VE - Venezuela 3
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
BO - Bolivia 2
CW - ???statistics.table.value.countryCode.CW??? 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
GD - Grenada 2
HN - Honduras 2
LB - Libano 2
LY - Libia 2
MA - Marocco 2
OM - Oman 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BT - Bhutan 1
BY - Bielorussia 1
CH - Svizzera 1
GE - Georgia 1
GP - Guadalupe 1
GR - Grecia 1
GT - Guatemala 1
HR - Croazia 1
IR - Iran 1
KG - Kirghizistan 1
KN - Saint Kitts e Nevis 1
KR - Corea 1
LV - Lettonia 1
MM - Myanmar 1
MT - Malta 1
MV - Maldive 1
NI - Nicaragua 1
NO - Norvegia 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SO - Somalia 1
TG - Togo 1
TN - Tunisia 1
Totale 5.117
Salva come PNG Salva come JPEG
Città #
Dublin 314
Chandler 309
San Jose 262
Singapore 234
Ashburn 209
Dallas 181
Hong Kong 175
Council Bluffs 138
Beijing 128
New York 65
Los Angeles 64
Boardman 57
Helsinki 56
Munich 53
Princeton 51
Lauterbourg 49
Ho Chi Minh City 47
Lawrence 46
Shanghai 42
Nanjing 34
Johannesburg 33
Hanoi 31
Chicago 29
Jacksonville 29
Medford 28
Wilmington 28
Moscow 25
Santa Clara 22
Buffalo 20
Pavia 19
Redondo Beach 19
Changsha 18
Nanchang 18
Vienna 18
Seattle 15
São Paulo 15
Frankfurt am Main 14
Orem 14
Milan 13
Montreal 13
Brooklyn 12
Fairfield 12
Falkenstein 12
Hangzhou 11
Hebei 11
Toronto 11
Phoenix 10
Turku 10
Brussels 9
Columbus 9
Jiaxing 9
London 9
Warsaw 9
Washington 9
Atlanta 8
Chennai 8
Da Nang 8
Dakar 8
Denver 8
Manchester 8
Shenyang 8
Tokyo 8
Ankara 7
Rome 7
San Francisco 7
Amman 6
Amsterdam 6
North Bergen 6
Tianjin 6
Albuquerque 5
Belo Horizonte 5
Berlin 5
Boston 5
Brno 5
Cagliari 5
Jakarta 5
Norwalk 5
Nuremberg 5
Rio de Janeiro 5
Tashkent 5
The Dalles 5
Guangzhou 4
Houston 4
Jeddah 4
Kuala Lumpur 4
Mexico City 4
Philadelphia 4
Poplar 4
Redwood City 4
San José 4
Stockholm 4
Ann Arbor 3
Anápolis 3
Brasília 3
Cape Town 3
Cleveland 3
Colombo 3
Genoa 3
Karachi 3
Manama 3
Totale 3.314
Salva come PNG Salva come JPEG
Nome #
The role of Trimethoprim/sulfametoxazole in reducing relapses and risk of infec-tions in ANCA-associated vasculitis: a meta-analysis 185
Is it really infective endocarditis? Distinguishing systemic vasculitis from its mimics 139
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 137
20 years of experience with tumour necrosis factor inhibitors: what have we learned? 131
Cytomegalovirus colitis unmasking human immunodeficiency virus infection as a cause of IgA vasculitis 129
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management 122
Fast-Track Ultrasound Clinic for the Diagnosis of Giant Cell Arteritis Changes the Prognosis of the Disease but Not the Risk of Future Relapse 119
Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs' 119
Cobalt hip prosthesis intoxication mimicking an autoimmune disease 119
Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes 117
Impact of immunosuppressive treatment on the immunogenicity of mRNA Covid-19 vaccine in vulnerable patients with giant cell arteritis 116
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 114
Anti-neutrophil cytoplasmic antibody specificity determines a different clinical subset in granulomatosis with polyangiitis 111
Blood biomarkers recommended for diagnosing and monitoring IgG4-related disease. Considerations from the ERN ReCONNET and collaborating partners 107
Risk of acute arterial and venous thromboembolic events in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss syndrome) 104
Novel Therapies for ANCA-associated Vasculitis 104
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies 103
Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis 103
Chronic pain: The burden of disease and treatment innovations 101
The role of extra-corporeal membrane oxygenation (ECMO) in the treatment of diffuse alveolar haemorrhage secondary to ANCA-associated vasculitis: report of two cases and review of the literature 101
Lumbar spondylolisthesis associated with systemic sclerosis-related spinal calcinosis: an unusual clinical case 100
Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis 99
Novel Diagnostic and Prognostic Approaches to Systemic Vasculitides 98
Clinical spectrum of anti-Jo-1-associated disease 96
Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment 95
Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs 95
Spinal non-Hodgkin’s lymphoma mimicking a flare of disease in a patient with ankylosing spondylitis treated with anti-TNF agents: case report and review of the literature 93
Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis 93
Azathioprine vs methotrexate in eosinophilic granulomatosis with polyangiitis: a monocentric retrospective study 93
Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors 90
Retention rate of IL-1 inhibitors in Schnitzler's syndrome 89
Early development of new cardiovascular risk factors in the systemic vasculitides 87
Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak 86
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev et al 82
Development and implementation of the AIDA International Registry for patients with Behçet’s disease 80
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage 79
Clinical course and outcome of COVID-19 in patients with rheumatic diseases: Are all biological disease-modifying antirheumatic drugs alike? Response to: Â € Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops et al 78
Switching from intravenous to subcutaneous formulation of abatacept: Different results in a series of 21 patients 75
Remission and Low-Disease Activity in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Prevalence and Impact on Damage Accrual 74
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: Ͽ Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and SLE, hydroxychloroquine and no SLE patients with COVID-19: A comment' by Joob and Wiwanitkit 72
Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? 72
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 69
Pneumocephalus due to granulomatosis with polyangiitis 67
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 66
The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta et al and 'Antirheumatic agents in covid-19: is IL-6 the right target?' by Capeechi et al 66
Striking abdominal aortic stenosis revealing Takayasu's arteritis 62
Pneumocephalus due to granulomatosis with polyangiitis 61
Derivation and validation of four patient clusters in Still's disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 60
Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: Lessons from a case with severe pneumonia' by Guilpain et al 59
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 58
Response to: 'Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic' by Lecler et al 58
mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients 57
How I treat idiopathic patients with inflammatory myopathies in the clinical practice 55
Prevalence of COVID-19 among patients with rheumatic diseases: The need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini et al 55
Interstitial lung disease in microscopic polyangiitis and granulomatosis with polyangiitis: demographic, clinical, serological and radiological features of an Italian cohort from the Italian Society for Rheumatology 53
Humoral and T-cell immune response following three doses of SARS-CoV-2 mRNA vaccine in giant cell arteritis: analysis of a prospective cohort 46
Non-steroidal anti-inflammatory treatment during covid-19: Friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo et al 46
Updates on the diagnosis and monitoring of giant cell arteritis 37
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease 28
Totale 5.210
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.485
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.485
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022185 0 0 0 2 4 14 1 11 9 6 27 111
2022/2023859 87 82 6 68 73 80 3 42 375 9 18 16
2023/2024396 63 75 18 16 30 83 25 32 3 20 15 16
2024/2025897 36 63 10 29 18 59 43 51 219 37 91 241
2025/20262.042 178 148 234 190 270 95 340 119 204 133 54 77
2026/2027515 89 114 120 192 0 0 0 0 0 0 0 0
Totale 5.210